Dataset from A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa

This study further evaluates the efficacy of bermekimab in treating moderate to severe
hidradenitis suppurativa in adults. 1/3 of patients will receive weekly injections of
bermekimab, 1/3 will receive alternating every other week injections of bermekimab or
placebo, and 1/3 will receive weekly injections of placebo.